Nonresident scholar Richard Kilroy explores how Mexican President Andrés Manuel López Obrador’s decision to move the Guardia Nacional — an institution created to protect public safety — under the control of Mexico’s military could have dire consequences for civil-military relations and U.S.-Mexico security relations.
The rapid adoption of telemedicine is one of the few positive developments of the COVID-19 pandemic, writes fellow Katharine Neill Harris. She explains why the DEA’s recent proposal to change the rules for prescribing drugs via telemedicine would harm patients and increase demand for and exposure to unregulated and more dangerous drugs.
In the United States, drug overdose deaths are on the rise. In 2022, CDC researchers reported that 110,236 people died from an overdose in a single 12-month period, setting a new record. Synthetic opioid overdose deaths, primarily due to fentanyl, increased nearly 7.5-fold from 2015 to 2021. In Texas, the number of fentanyl-related deaths rose dramatically — from 883 deaths in 2020 to 1,672 deaths in 2021. While Republican lawmakers in Texas have previously opposed harm reduction policies, many have signaled a desire to take policy action to combat the crisis in the 2023 legislative session.
David M. Satterfield, Edward M. Emmett, The Honorable Ed Gonzalez, Katharine Neill Harris, The Honorable Kim OggMarch 8, 2023
A pledge to boost regional competitiveness is a welcome outcome of last month's North American Leaders’ Summit. But the region’s policymakers should remember the lessons of the past as they work to do so, writes fellow David A. Gantz.
In 2022, the nation faced fundamental questions about how we govern our economy and society — particularly how we formulate public policy. Here, we share 10 highlights of our work that illustrate our impact from the previous year.
On October 12, 2022, Katharine Neill Harris, the Alfred C. Glassell, III, Fellow in Drug Policy, testified before the Texas House of Representatives Interim Study Committee on Criminal Justice Reform. Her written testimony addresses the committee's inquiry into policies and penalties relating to drug offenses.
There have been promising developments in recent years in the fight to reduce overdose deaths. But barriers to drug checking and other overdose prevention tools remain throughout the country, writes fellow Katharine Neill Harris.